Brief: Ipsen To Acquire Memo Therapeutics AG, Adding First-In-Class BK Polyomavirus Antibody

Ipsen SA

01/07/2026 06:08

July 1 (Reuters) - Ipsen SA IPN.PA:
IPSEN TO ACQUIRE MEMO THERAPEUTICS AG, ADDING FIRST-IN-CLASS BK POLYOMAVIRUS ANTIBODY, EXPANDING RARE DISEASE PORTFOLIO
DEAL VALUED AT EUR 200 MILLION UPFRONT, POTENTIAL OVER EUR 700 MILLION
DEAL EXPECTED TO CLOSE IN Q3 2026
IMPACT OF THIS PROPOSED MID-STAGE ACQUISITION IS FACTORED INTO IPSEN CURRENT FY GUIDANCE
ANTICIPATED ACQUISITION IS FOCUSED ON POTRAVITUG, WHICH IS A PHASE II CLINICAL-STAGE ANTIBODY AGAINST BK POLYOMAVIRUS (BKPYV)
Source text: nGNE3gtTMD
Further company coverage: IPN.PA

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))